







an Open Access Journal by MDPI

## 30 Years of OPN Milestones and Future Avenues 2.0

Guest Editor:

### Dr. Giuseppe Cappellano

Department of Health Sciences, Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy

Deadline for manuscript submissions:

closed (31 August 2023)

## **Message from the Guest Editor**

Understanding how OPN is processed and interacts with its natural ligands is of paramount importance for elucidating the complex role that this protein plays in human diseases.

Herein, in this Commemorative Issue, authors are invited to review recent work or submit original studies in all areas of recent and current OPN research, with an emphasis on work providing molecular insight, including, but not limited to, novel physiological and pathological functions, or regulatory mechanisms.

Thus, let us stop counting OPN years and start making them count!













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

# **Message from the Editor-in-Chief**

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

#### **Contact Us**